Plain-English translation of NCT06200103 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a medication called 177Lu-PSMA-617, which is a radioactive treatment designed to attack prostate cancer cells. The study wants to find out whether men whose cancer shrinks significantly after receiving this treatment can safely pause for a while, or whether they should continue getting the treatment on a regular schedule. The goal is to help doctors understand the best way to give this medication with the fewest side effects.
This medication has shown promise in treating advanced prostate cancer that no longer responds to hormone therapy, but doctors don't yet know the optimal treatment schedule. This trial will help determine whether patients can maintain their good results with fewer treatment cycles, which could reduce side effects while keeping cancer under control.
You likely qualify if…
You likely don't qualify if…
You will start by receiving the radioactive medication as an intravenous infusion every 6 weeks for up to 5 treatment cycles, along with imaging scans to monitor how your cancer responds. After showing a strong response on imaging, you will be randomly assigned to either continue regular treatment or take a pause and be monitored closely. If you're in the pause group and your cancer starts growing again, you'll resume treatment. Throughout the study, you'll have regular blood tests, imaging scans, and quality-of-life questionnaires to track how you're doing.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
United States